Neuronascent signs small-molecules screening agreement with Russia's Chemrar
This article was originally published in Scrip
Executive Summary
Neuronascent, a private US biotech company, has signed an agreement with Moscow-based Chemrar, under which it will screen Chemrar's pathway inhibitors using its technology for identifying neurogenic and neuroprotective drug candidates. Financial terms have not been disclosed.